Erratum: Pharmacologic Approaches to Glycemic Treatment. Sec. 8. In Standards of Medical Care in Diabetesd 2017 (Diabetes Care (2017) 40 (Suppl. 1) (S64-S74) DOI: 10.2337/dc17-S011);Pharmacologic approaches to glycemic treatment

Diabetes Care

Volumn 40, Issue , 2017, Pages S64-S74

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALOGLIPTIN; BROMOCRIPTINE; CANAGLIFLOZIN; COLESEVELAM; DAPAGLIFLOZIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INSULIN; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; PLACEBO; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; UNINDEXED DRUG;

ARTICLE; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; DIABETES EDUCATION; DRUG EFFICACY; GLOMERULUS FILTRATION RATE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PANCREAS ISLET TRANSPLANTATION; PANCREAS TRANSPLANTATION;

EID: 85009168575     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc17-er07b     Document Type: Erratum

References (48)

1. American Diabetes Association, JDRF. American Diabetes Association/JDRF Type 1 Diabetes Sourcebook. Peters AL, Laffel L, Eds. Alexandria, VA, American Diabetes Association, 2013
2. Chiang JL, Kirkman MS, Laffel LMB, Peters AL. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care 2014;37:2034-2054
3. Wolpert HA, Atakov-Castillo A, Smith SA, Steil GM. Dietary fat acutely increases glucose concentrations and insulin requirements in patients with type 1 diabetes: implications for carbohydrate-based bolus dose calculation and intensive diabetes management. Diabetes Care 2013;36:810-816
4. Bell KJ, Toschi E, Steil GM, Wolpert HA. Optimized mealtime insulin dosing for fat and protein in type 1 diabetes: application of a model-based approach to derive insulin doses for open-loop diabetes management. Diabetes Care 2016;39:1631-1634
5. Bell KJ, Smart CE, Steil GM, Brand-Miller JC, King B, Wolpert HA. Impact of fat, protein, and glycemic index on postprandial glucose control in type 1 diabetes: implications for intensive diabetes management in the continuous glucose monitoring era. Diabetes Care 2015;38:1008-1015
6. Yeh H-C, Brown TT,Maruthur N, et al. Comparative effectiveness and safety of methods of insulin delivery and glucosemonitoring for diabetes mellitus: a systematic review and meta-analysis. Ann Intern Med 2012;157:336-347
7. Bergenstal RM, Klonoff DC, Garg SK, et al. ; ASPIRE In-Home Study Group. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med 2013;369:224-232
8. Wood JR, Miller KM, Maahs DM, et al. ; T1D Exchange Clinic Network. Most youth with type 1 diabetes in the T1D Exchange Clinic Registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes clinical guidelines. Diabetes Care 2013;36:2035-2037
9. Kmietowicz Z Insulin pumps improve control and reduce complications in children with type 1 diabetes. BMJ 2013;347:f5154
10. Phillip M, Battelino T, Atlas E, et al. Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med 2013;368:824-833
11. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
12. Nathan DM, Cleary PA, Backlund J-YC, et al. ; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653
13. Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Mortality in type 1 diabetes in the DCCT/EDIC versus the general population. Diabetes Care 2016;39:1378-1383
14. DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: scientific review. JAMA 2003;289:2254-2264
15. Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005;28:950-955
16. Bode BW,McGill JB, Lorber DL,Gross JL, Chang PC, Bregman DB; Affinity 1 Study Group. Inhaled technosphere insulin compared with injected prandial insulin in type 1 diabetes: a randomized 24-week trial. Diabetes Care 2015;38:2266-2273
17. American Diabetes Association. Pancreas and islet transplantation in type 1 diabetes. Diabetes Care 2006;29:935
18. Vella S, Buetow L, Royle P, Livingstone S, Colhoun HM, Petrie JR. The use of metformin in type 1 diabetes: a systematic review of efficacy. Diabetologia 2010;53:809-820
19. U.S. Food and Drug Administration. SGLT2 Inhibitors: Drug Safety Communication-Labels to Include Warnings About Too Much Acid in the Blood and Serious Urinary Tract Infections [Internet]. Available from http://www.fda .gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm475553 .htm. Accessed 3 October 2016
20. Palmer SC, Mavridis D, Nicolucci A, et al. Comparison of clinical outcomes and adverse events associated with glucose-lowering drugs in patients with type 2 diabetes: a meta-analysis. JAMA 2016;316:313-324
21. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-149
22. Holman RR, Paul SK, BethelMA,Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359: 1577-1589
23. Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011;154:602-613
24. U.S. Food and Drug Administration. Metformincontaining Drugs: Drug Safety Communication-Revised Warnings for Certain Patients With Reduced Kidney Function [Internet]. Available from http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedical Products/ucm494829.htm?source5govdelivery& utm-medium5email&utm-source5govdelivery. Accessed 3 October 2016
25. Aroda VR, Edelstein SL, Goldberg RB, et al. ; Diabetes Prevention Program Research Group. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab 2016;101: 1754-1761
26. Vijan S, Sussman JB, Yudkin JS, Hayward RA. Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus. JAMA Intern Med 2014;174:1227-1234
27. Institute for Clinical and Economic Review. Controversies in the Management of Patients with Type 2 Diabetes [Internet]. Available from http://icer-review.org/wp-content/uploads/2015/03/CEPAC-T2D-Final-Report-December-22.pdf. Accessed 17 November 2016
28. Nathan DM, Buse JB, Kahn SE, et al. ; GRADE Study Research Group. Rationale and design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care 2013;36:2254-2261
29. Zinman B, Wanner C, Lachin JM, et al. ; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128
30. Marso SP, Daniels GH, Brown-Frandsen K, et al. ; LEADER Steering Committee; LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311-322
31. Green JB, Bethel MA, Armstrong PW, et al. ; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232-242
32. Scirica BM, Bhatt DL, Braunwald E, et al. ; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-1326
33. White WB, Cannon CP, Heller SR, et al. ; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-1335
34. Blonde L, Merilainen M, Karwe V, Raskin P; TITRATE Study Group. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets-the TITRATE study. Diabetes Obes Metab 2009;11: 623-631
35. Tricco AC, Ashoor HM, Soobiah C, et al. Safety, effectiveness, and cost of long-acting versus intermediate-acting insulin for type 1 diabetes: protocol for a systematic review and network meta-analysis. Syst Rev 2013;2:73
36. Hua X, Carvalho N, Tew M, Huang ES, Herman WH, Clarke P. Expenditures and prices of antihyperglycemic medications in the United States: 2002-2013. JAMA 2016;315: 1400-1402
37. Diamant M, Nauck MA, Shaginian R, et al. ; 4B Study Group. Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Diabetes Care 2014;37: 2763-2773
38. Eng C, Kramer CK, Zinman B, Retnakaran R. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis. Lancet 2014;384: 2228-2234
39. Dieuzeide G, Chuang L-M, Almaghamsi A, Zilov A, Chen J-W, Lavalle-Gonz ález FJ. Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study. Prim Care Diabetes 2014;8:111-117
40. Mathieu C, Storms F, Tits J, Veneman TF, Colin IM. Switching from premixed insulin to basal-bolus insulin glargine plus rapid-acting insulin: the ATLANTIC study. Acta Clin Belg 2013; 68:28-33
41. Giugliano D, Chiodini P, Maiorino MI, Bellastella G, Esposito K. Intensification of insulin therapy with basal-bolus or premixed insulin regimens in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Endocrine 2016;51:417-428
42. Kernan WN, Viscoli CM, Furie KL, et al. ; IRIS Trial Investigators. Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 2016;374:1321-1331
43. Dormandy JA, Charbonnel B, Eckland DJA, et al. ; PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-1289
44. Chiasson J-L, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetesmellitus: the STOP-NIDDMrandomised trial. Lancet 2002;359:2072-2077
45. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
46. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-865
47. Gaziano JM, Cincotta AH, O'Connor CM, et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 2010;33:1503-1508
48. Truven Health Analytics. Red Book: A Comprehensive, Consistent Drug Pricing Resource [Internet], 2016. Available from http://micromedix .com/products/product-suites/clinical-knowledge/redbook. Accessed 29 July 2016